Clinical trials: Disease Free Survival
Aspirin as an Adjuvant Therapy, to Observe Its Effect on the Disease Free Survival Rate of Patients With Esophageal Squamous Cell Carcinoma
Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma
Esophageal cancers are the seventh most common cancer in the world and one of the most common causes of cancer deaths. In some parts of China, the incidence of SCC is among the highest in the world.
- Trial name
- NCT03900871
- Testing
- Acetylsalicylic acid
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Hebei Medical University Fourth Hospital
Melanoma
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer.
- Trial name
- NCT01740401
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Renal Cell Carcinoma ( mRCC)
Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC
The goal of this clinical trial is to learn whether the timing of surgery (cytoreductive nephrectomy) improves outcomes when combined with immunotherapy (ipilimumab and nivolumab) in adults with metastatic clear cell renal cell…
- Trial name
- IVE in mRCC (NCT07233668)
- Testing
- Ipilimumab plus Nivolumab, Cytoreductive Nephrectomy
- Volunteers
- 172 people
- Sponsor
- Seoul National University Hospital
Breast Cancer
A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression
This single arm study will assess the efficacy of Xeloda in the treatment of brain metastases in breast cancer patients with central nervous system (CNS) progression after whole brain radiotherapy.
- Trial name
- NCT01077726
- Testing
- capecitabine [Xeloda]
- Where
- 12 sites in France
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Ovarian Neoplasms Malignant, Sleep Initiation and Maintenance Disorders
Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer
Study Title: A Multicenter, Randomized Controlled Trial of Tiaoshen Anti-cancer Protocol Combined with Cognitive Behavioral Therapy for Insomnia in Improving Sleep and Survival in Ovarian Cancer Patients Purpose: This study aims…
- Conditions
- Ovarian Neoplasms Malignant, Sleep Initiation and Maintenance Disorders, Medicine, Chinese Traditional, Chinese Herbal Medicine
- Trial name
- NCT07550205
- Testing
- Tiaoshen Anti-cancer Granules, Cognitive Behavioral Therapy for Insomnia, Standard First-line Platinum-based Chemotherapy
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
Adaptation, Psychological, Functional Insufficiency
Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery
The purpose of the study is to investigate whether there are prognostic factors regarding the mental and functional adjustment of colon cancer patients following curative surgery.
- Trial name
- NCT01675505
- Where
- Greece
- Volunteers
- 80 people
- Sponsor
- Aristotle University Of Thessaloniki
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Background: Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return.
- Conditions
- Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
- Trial name
- NCT05642195
- Testing
- Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Colon
Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer
The human body has a natural stress response to surgery, including the formation of blood clots. This response to surgery has been shown to increase metastases (the spread of cancer cells to other organs in the body).
- Trial name
- PERIOP-01 (NCT01455831)
- Testing
- Tinzaparin
- Where
- 16 sites in Belgium, Canada and 1 more
- Volunteers
- 616 people
- Sponsor
- Ottawa Hospital Research Institute
Untreated Chronic Lymphocytic Leukemia
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.
- Trial name
- NCT04075292
- Testing
- Acalabrutinib, Rituximab, Chlorambucil
- Where
- 46 sites in China, Philippines and 3 more
- Volunteers
- 155 people
- Sponsor
- AstraZeneca
Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer.
- Conditions
- Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
- Trial name
- DNADalHR (NCT06970912)
- Testing
- Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Peking University People's Hospital
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Prostate Cancer
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
This multinational, multicenter, prospective, randomized, controlled, open label Phase 3 study is designed to investigate and confirm the benefits and risks associated with the PSMA-targeted antibody, 177Lu DOTA rosopatamab…
- Trial name
- NCT04876651
- Testing
- 177Lu-DOTA-rosopatamb, Standard of Care
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 16 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Breast Cancer
Overall Survival and Disease-free Survival in Breast Cancer Patients Under COS
The main objective of the study is to evaluate the overall survival and disease-free survival in breast cancer patients under 40 years old.
- Trial name
- NCT02745262
- Testing
- Collect retrospectively the follow-up data
- Volunteers
- 400 people
- Sponsor
- IVI Vigo
Lung Cancers, Lung Cancer, Non-Small Cell
Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer
By 2020, lung cancer continues leading the first cause of cancer mortality and the second most common type of cancer in the world.
- Trial name
- FACT-L_Pred (NCT06900283)
- Where
- Colombia
- Volunteers
- 320 people
- Sponsor
- Instituto Nacional de Cancerologia, Columbia
Diffuse Large B Cell Lymphoma
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line
Diffuse large B cell lymphoma is the most common histology of non-Hodgkin's malignant lymphomas (31% of lymphomas), with an incidence of between 15 and 20 new cases per year per 100,000 inhabitants in France.
- Trial name
- PHARAOM (NCT04670029)
- Testing
- Adapted physical activity
- Where
- 5 sites in France
- Volunteers
- 186 people
- Sponsor
- Weprom
Colorectal Cancer Metastatic, Liver Metastases
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Patients presenting with multiple innumerable liver metastases will probably never come to resection, however, for all others, including patients with numerous multiple metastases or large metastases, resection should be…
- Conditions
- Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer
- Trial name
- BOS3 (NCT01646554)
- Testing
- Modified FOLFOX6, Aflibercept, Surgery
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
High-Risk Cancer, Urothelial Carcinoma Bladder
Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer
This is a prospective randomized clinical trial in high risk urothelial bladder cancer to compare adjuvant radiotherapy versus observation after radical cyctectomy.
- Trial name
- NCT04740866
- Testing
- Adjuvant Radiotherapy
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Acute Myeloid Leukemia (AML)
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR<0.05) AML (FLT3…
- Trial name
- NCT03512197
- Testing
- Midostaurin, Chemotherapy
- Where
- 133 sites in United States, Argentina and 18 more
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5
Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5
Patients with severe, rapidly progressive diffuse interstitial lung disease (RP ILD) with anti-MDA5 have an appalling prognosis and the lack of effective medical treatment leads to lung transplantation being proposed as salvage…
- Trial name
- TEAM MDA5 (NCT07631208)
- Testing
- Teclistamab(SC)
- Volunteers
- 24 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
This study will examine the relationship of a protein called pAKT to survival of breast cancer patients with one or more positive axillary lymph nodes.
- Trial name
- NCT00965276
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- National Cancer Institute (NCI)